UroGen Pharma to Showcase Cancer Therapies at Goldman Sachs Healthcare Conference
Event summary
- UroGen Pharma will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026, at 8:40 AM ET.
- The presentation will include a fireside chat and 1x1 investor meetings in Miami Beach, FL.
- UroGen focuses on non-surgical treatments for urothelial and specialty cancers using its RTGel platform technology.
- The company has two approved products for treating low-grade upper tract urothelial cancer and recurrent LG-IR-NMIBC.
The big picture
UroGen’s participation in the Goldman Sachs conference underscores its push to position itself as a leader in non-surgical cancer treatments. The event provides a critical opportunity to showcase its proprietary RTGel technology to a broad audience of investors and industry stakeholders. As the biotech sector continues to prioritize targeted therapies, UroGen’s ability to differentiate itself through sustained-release hydrogel solutions will be key to its long-term success.
What we're watching
- Commercialization Strategy
- How UroGen will leverage this high-profile platform to drive investor interest and potential partnerships.
- Market Differentiation
- Whether UroGen’s RTGel technology can sustain competitive advantage in the urothelial cancer treatment space.
- Regulatory Landscape
- The pace at which UroGen can expand its approved indications for existing products.
Related topics